This phase I trial studies the side effects and best dose of anti-PD-L1/TGFbetaRII fusion
protein M7824 (M7824) when given together with radiation therapy in treating patients with
hormone receptor positive, HER2 negative breast cancer that has spread to other parts of the
body. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. M7824
is a drug that targets specific proteins on immune cells in order to activate immune
responses against tumor cells. Giving M7824 together with radiation therapy may work better
in treating patients with breast cancer.
I. To determine the recommended phase II dose (RP2D) of M7824 and radiation therapy in
patients with metastatic hormone receptor positive (HR+)/HER2 negative (-) breast cancer.
II. To evaluate the safety and tolerability of M7824 and radiation therapy in patients with
metastatic HR+/HER2- breast cancer.
I. To assess immunologic/molecular responses, specifically percentage (%) change in
tumor-infiltrating lymphocytes (TIL) pre and post therapy to M7824 and radiation therapy in
patients with HR+/HER2- metastatic breast cancer.
II. To explore progression free survival (PFS) and overall survival (OS) to power future
III. To evaluate the in-field and abscopal effect of treatment with anti-PD-L1/TGF-beta trap
(M7824) and radiation therapy.
I. To characterize the effect of anti-PD-L1/TGF-beta trap (M7824) and radiation therapy on
immune biomarkers including PD-L1 expression and fibrosis changes in tumor microenvironment
in tumor tissue obtained from subjects pre- and post-treatment.
II. To characterize circulating immune cell populations and cytokine profiles in tumor and
circulation following treatment with M7824.
III. To conduct ribonucleic acid sequencing (RNAseq), RNA Scope, whole exome sequencing (WES)
targeted sequencing and tissue IO gene expression.
Patients receive M7824 intravenously (IV) over 1 hour every 14 days. Cycles repeat every 28
days in the absence of disease progression or unacceptable toxicity. Beginning within 3 days
after second dose of M7824, patients undergo radiation therapy once a day (QD) for 5-10 days
depending on the site of disease in the absence of disease progression or unacceptable
After completion of study treatment, participants are followed up for 90 days.
- Is willing and able to provide written informed consent for the trial and has signed
the appropriate written informed consent form, approved by the investigator's
Institutional Review Board (IRB)/Independent Ethics Committee (IEC), prior to the
performance of any trial activities.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
- Highly effective contraception for both male and female subjects if the risk of
conception exists. Highly effective contraception must be used 30 days prior to first
trial administration, for the duration of trial treatment, and at least for 4 months
after stopping trial treatment. Should a woman become pregnant or suspect she is
pregnant while she or her partner is participating in this trial, the treating
physician should be informed immediately.
- Has confirmed HR+ and HER2 negative breast cancer with known metastatic disease. HR
defined as positive if expression greater than 10% by immunohistochemistry (IHC). HER2
negative or non-amplified is determined by the current American Society of Clinical
Oncology-College of American Pathologists (ASCO-CAP) criteria which are as follows:
HER2 testing by IHC as 0 or 1+. If HER2 is 2+, ISH (in situ hybridization) must be
performed. HER2 is positive if: i. IHC 3+ based on circumferential membrane staining
that is a. complete, intense ii. ISH positive based on: a. single-probe average HER2
copy number >= 6.0 signals/cell. b. Dual-probe HER2/CEP17 ratio >= 2.0 with an average
HER2 copy number >= 4.0 signals/cell c. Dual-probe HER2/CEP17 ratio >= 2.0 with an
average HER2 copy number < 4.0 signals/cell d. Dual-probe HER2/CEP17 ratio < 2.0 with
an average HER2 copy number >= 6.0 signals/cell.
- Has at least 2 identified sites of metastatic disease by imaging.
- Has received no more than 5 previous lines of chemotherapy and has received at least
one line of therapy with an endocrine therapy or endocrine therapy combination.
- White blood cell (WBC) count >= 3 x 10^9/L.
- Absolute neutrophil count (ANC) >= 1.5 x 10^9/L.
- Lymphocyte count >= 0.5 x 10^9/L.
- Platelet count >= 100 x 10^9/L.
- Hemoglobin (Hgb) >= 9 g/dL.
- Total bilirubin level =< 1.5 x the upper limit of normal (ULN).
- Aspartate aminotransferase (AST) level =< 2.5 x ULN.
- Alanine aminotransferase (ALT) level =< 2.5 x ULN.
- International normalized ratio (INR) < 1.5.
- Adequate renal function defined by an estimated creatinine clearance > 30 mL/min
according to the Cockcroft-Gault formula or be measure for creatinine clearance from
24 hour urine collection.
- Has not had major surgery within 28 days prior to starting study treatment. Central
venous access surgeries and/or placements would not be considered as major surgery.
- Is eligible for palliative radiotherapy as determined by the treating radiation
- Anticancer treatment within 14 days before the start of trial treatment (e.g.,
cytoreductive therapy, radiotherapy [with the exception of palliative radiotherapy
delivered in a normal organ-sparing technique], immune therapy, or cytokine therapy).
- Major surgery as determined by the investigator within 28 days before the start of
trial treatment (prior diagnostic biopsy is permitted).
- Systemic therapy with immunosuppressive agents within 7 days before the start of
treatment; or use of any investigational drug within 28 days before the start of trial
- Subjects with active central nervous system (CNS) metastases with significant
neurological compromise or symptoms are excluded. Subjects with a history of treated
CNS metastases (by surgery or radiation therapy), who show no evolving new
neurological symptoms are eligible for the study.
- Receipt of any organ transplantation, including allogeneic stem-cell transplantation,
but with the exception of transplants that do not require immunosuppression (e.g.,
corneal transplant, hair transplant).
- Significant acute or chronic infections including, among others: a. Known history of
testing positive test for human immunodeficiency virus (HIV) or known acquired
immunodeficiency syndrome. b. Active hepatitis B virus (HBV) (HBV surface antigen
positive) or hepatitis C virus (HCV) (HCV RNA positive). c. Subjects with known active
tuberculosis (history of exposure or history of positive tuberculosis test plus
presence of clinical symptoms, physical or radiographic findings).
- Active autoimmune disease that might deteriorate when receiving an immunostimulatory
agent: a. subjects with type I diabetes, vitiligo, alopecia, psoriasis, hypo- or
hyperthyroid disease not requiring immunosuppressive treatment are eligible b.
subjects requiring hormone replacement with corticosteroids are eligible if the
steroids are administered only for the purpose of hormonal replacement and at doses 10
mg of prednisone or equivalent per day.
- Clinically significant cardiovascular/cerebrovascular disease as follows: cerebral
vascular accident/stroke (< 6 months prior to enrollment), myocardial infarction (< 6
months prior to enrollment), unstable angina, congestive heart failure (New York Heart
Association classification class > II), or serious cardiac arrhythmia.
- Clinically relevant diseases (for example, inflammatory bowel disease) and /or
uncontrolled medical conditions, which, in the opinion of the investigator, might
impair the subject's tolerance or ability to participate in the trial.
- Vaccine administration within 4 weeks of M7824 administration. Vaccination with live
vaccines while on trial is prohibited. Administration of inactivated vaccines is
allowed (for example, inactivated influenza vaccines).
- Pregnancy and breast feeding.
- History of conditions associated with bleeding diatheses.